LIA
PCVX icon

Lynx Investment Advisory’s Vaxcyte PCVX Stock Holding History

Lynx Investment Advisory’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-26
Closed -$1.96K – 589
2024
Q2 		$1.96K Buy
+26
New +$1.77K ﹤0.01% 575

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lynx Investment Advisory's PCVX Position: Q3 2024 in Review

Lynx Investment Advisory sold out of Vaxcyte (PCVX) in Q3 2024, closing a stake of 26 shares — an estimated $1.96K sold.

Lynx Investment Advisory first reported a position in PCVX in Q2 2024 and held it in 1 quarter. The position peaked at $1.96K in Q2 2024. 328 funds tracked by Wall St. Rank hold PCVX as of Q3 2024.

  • Lynx Investment Advisory reported no remaining Vaxcyte position as of Q3 2024 after selling out during the quarter.
  • Lynx Investment Advisory sold 26 Vaxcyte shares in Q3 2024, an estimated $1.96K.
  • Lynx Investment Advisory first reported a position in Vaxcyte in Q2 2024 and held it in 1 quarter.
  • Lynx Investment Advisory's Vaxcyte position peaked at $1.96K in Q2 2024.
  • 328 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2024.

Based on Lynx Investment Advisory's 13F filing for Q3 2024, filed 4 Nov 2024.